Table 2.
Pharmacokinetic results per period
| Pharmacokinetic parameters | No PPI with water [n = 14] | No PPI with milk [n = 14] | PPI with water [n = 15] | PPI with milk [n = 15] | RD, no-PPI with milk vs. no-PPI with water (95% CI) | p value | RD, PPI with milk vs. PPI with water (95% CI) | p value |
|---|---|---|---|---|---|---|---|---|
| Erlotinib | ||||||||
| AUC24 (CV%), geomean μg*h/mL | 23.0 (37) | 22.4 (35) | 11.7 (61) | 11.6 (38) | − 2.7% (− 12 to 8%) | 0.567 | − 0.5% (− 15 to 17%) | 0.953 |
| Cmax (CV %), geomean μg/mL | 1.85 (38) | 1.73 (21) | 0.81 (55) | 0.82 (40) | − 6.4% (− 21 to 11%) | 0.409 | 1.5% (− 12 to 17%) | 0.831 |
| Tmax (IQR), median hours | 2.00 (1.52–2.50) | 2.50 (2.00–3.00) | 2.52 (2.05–3.50) | 3.00 (2.50–3.52) | NA | 0.729 | NA | 0.306 |
AUC24 area under the curve from time zero to 24 h, CI confidence interval, RD relative difference, Cmax maximum concentration, CV coefficient of variation, Tmax time until maximum concentration, IQR interquartile range, NA not applicable, PPI proton pump inhibitor